Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BONTRIL PDM vs ETHRANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
FDA-approved: Chronic weight management (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity) as an adjunct to a reduced-calorie diet and increased physical activity.,Off-label: None widely recognized.
Induction and maintenance of general anesthesia
Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
Terminal elimination half-life is 12-15 hours in adults, prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Phentermine: primarily renal excretion (unchanged). Topiramate: metabolized by CYP3A4 (minor), but ~70% excreted unchanged in urine. Also undergoes hydrolysis and glucuronidation.
Primarily hepatic via cytochrome P450 (CYP2E1); minor metabolism to fluoride ions.
Renal: ~70% (unchanged), Fecal: ~30% (biliary excretion of metabolites).
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
98% bound to albumin.
Approximately 30-40%, primarily to albumin.
0.25-0.35 L/kg, indicating distribution primarily in extracellular fluid.
Vd: 1.2-2.0 L/kg, indicating extensive distribution into tissues, especially fat.
Oral: 65-75% (first-pass metabolism); IM: 85-95%.
By inhalation: 100% as delivered; not administered orally.
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, reduce dose by 50%. GFR <10 m L/min: Contraindicated.
No dose adjustment required for GFR >10 m L/min; use with caution in severe renal impairment (GFR <10 m L/min) due to potential accumulation of inorganic fluoride metabolites.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment as metabolism may be decreased.
Children 6-12 years: 2.5-5 mg once daily; maximum 10 mg/day. Children >12 years: Same as adult dosing.
Induction: 2-5% inspired concentration; Maintenance: 1-3% inspired concentration, adjusted to age and response.
Initiate at 2.5 mg once daily; may increase to 5 mg if needed. Use with caution due to increased sensitivity.
Lower inspired concentrations (0.5-2%) recommended due to increased sensitivity and reduced clearance; titrate to effect.
No black box warning for the combination product. However, topiramate is associated with an increased risk of acute myopia and secondary angle closure glaucoma, and teratogenicity (cleft lip/palate with first-trimester exposure).
None
Acute myopia and angle-closure glaucoma (topiramate); discontinue if symptoms occur.,Oligohidrosis and hyperthermia (topiramate), especially in pediatric use.,Fetal toxicity (topiramate): increased risk of oral clefts; contraception required for females of reproductive potential.,Suicidal behavior or ideation (topiramate).,Metabolic acidosis (topiramate): monitor serum bicarbonate.,Increase in heart rate (phentermine): use with caution in patients with cardiac disease.,Pulmonary hypertension (phentermine): rare but serious.,Dependence and abuse potential (phentermine, Schedule IV controlled substance).,Glaucoma angle closure risk.,Kidney stones (topiramate): hydrate to prevent.,Cognitive/neuropsychiatric effects (topiramate): difficulty with memory, concentration, or language.
May cause dose-dependent cardiovascular depression,Risk of malignant hyperthermia,Potential for nephrotoxicity due to fluoride release,Hepatotoxicity risk, especially with repeated use,Neurologic effects including seizure activity at high doses
Glaucoma (angle-closure), especially with topiramate component.,Hyperthyroidism (phentermine).,Patients with a history of drug abuse (phentermine).,MAO inhibitor use within 14 days (phentermine).,Pregnancy (topiramate is teratogenic).,Breastfeeding (safety not established).,Known hypersensitivity to phentermine or topiramate.,Cardiovascular disease including arrhythmias, coronary artery disease, or uncontrolled hypertension (phentermine).,Concomitant use of other central nervous system stimulants.
Known hypersensitivity to enflurane or other halogenated anesthetics,Known or suspected susceptibility to malignant hyperthermia,Severe hepatic impairment,Uncontrolled epilepsy
Avoid alcohol and caffeine-containing products. High-fat meals may delay absorption. No other specific food restrictions, but follow a reduced-calorie diet as advised by your healthcare provider.
No specific food interactions. Patient must follow preoperative fasting guidelines (nil per os, NPO) as directed by anesthesiologist to reduce risk of aspiration.
First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal hemorrhage and premature closure of ductus arteriosus.
FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal hypoxia from maternal hypotension.
Excreted into breast milk with M/P ratio of 0.8. Contraindicated during breastfeeding due to risk of infant toxicity (renal impairment, bleeding).
Excreted in breast milk in low amounts; M/P ratio not established. Consider benefits of breastfeeding vs. risk of infant exposure. Minimal systemic absorption in infant expected.
No established safe dose due to teratogenicity. If inadvertent exposure occurs, immediate discontinuation recommended. No dose adjustment is feasible given contraindication.
No specific dose adjustments required for pregnancy; however, MAC decreases by approximately 30% during pregnancy due to hormonal changes and increased progesterone. Monitor depth of anesthesia closely.
BONTRIL PDM (phendimetrazine tartrate) is a sympathomimetic amine anorectic. Monitor blood pressure and heart rate due to potential increases. Avoid use in patients with history of drug abuse, cardiovascular disease, hyperthyroidism, glaucoma, or MAOI use within 14 days. Taper to avoid abrupt discontinuation. Not recommended for pediatric patients or those with hypertension.
ETHRANE (enflurane) is a potent inhalation anesthetic. Its use is limited due to risk of seizures at high doses and potential for nephrotoxicity from fluoride ion release. Avoid in patients with history of seizures or renal impairment. Rapid induction and recovery; use with caution in hypotensive patients due to myocardial depression. Malignant hyperthermia trigger.
Take exactly as prescribed; do not exceed recommended dose.,Avoid driving or operating machinery until you know how this medication affects you.,Report chest pain, shortness of breath, or palpitations immediately.,Do not take with other stimulants or diet aids.,Inform your doctor if you become pregnant or plan to breastfeed.,Do not stop suddenly without consulting your doctor.
You will receive this anesthesia medication only in a hospital setting under expert supervision.,Possible side effects include nausea, vomiting, shivering, and confusion after waking up.,Tell your doctor if you have a history of seizures, kidney problems, or muscle disorders.,Avoid driving or operating machinery for at least 24 hours after anesthesia.,Do not eat or drink for the time specified by your healthcare team before surgery.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BONTRIL PDM vs ETHRANE, answered by our medical review team.
BONTRIL PDM is a Sympathomimetic Anorectic that works by Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the release of norepinephrine and dopamine in the hypothalamus, reducing food intake. Topiramate is a sulfamate-substituted monosaccharide that enhances GABAergic activity and inhibits glutamatergic neurotransmission via AMPA/kainate receptors, leading to appetite suppression and increased energy expenditure.. ETHRANE is a General Anesthetic that works by Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BONTRIL PDM and ETHRANE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BONTRIL PDM is: Oral: 5-10 mg once daily in the morning; maximum 20 mg/day. Oral disintegrating tablet: 5-10 mg once daily.. The standard adult dose of ETHRANE is: 1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BONTRIL PDM and ETHRANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BONTRIL PDM is classified as Category C. First trimester: Category X. Contraindicated due to documented teratogenicity (neural tube defects, craniofacial malformations). Second/third trimester: Avoid due to risk of fetal . ETHRANE is classified as Category C. FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.